Latest Updates

Pediatric Tumors: Rhabdomyosarcoma

John Groundland, MD, MS, R L Randall, MD, FACS, Sara Shaw, BS
    • Classification of rhabdomyosarcoma (RMS) into groups and variants has led to improved understanding of disease prognosis and the need for tailored intervention.
    • Multiagent chemotherapy with surgical excision and/or therapeutic radiation has led to an overall improvement in 5-year survival of RMS from 25 to 75% between 1970 and 2010.
    • Despite improvement in survival of low- and intermediate-risk RMS patients, patients with high-risk RMS or recurrent disease continue to respond inadequately to treatment and have poor survival outcomes.

Pediatric Tumors: Rhabdomyosarcoma

John Groundland, MD, MS, R L Randall, MD, FACS, Sara Shaw, BS
    • Classification of rhabdomyosarcoma (RMS) into groups and variants has led to improved understanding of disease prognosis and the need for tailored intervention.
    • Multiagent chemotherapy with surgical excision and/or therapeutic radiation has led to an overall improvement in 5-year survival of RMS from 25 to 75% between 1970 and 2010.
    • Despite improvement in survival of low- and intermediate-risk RMS patients, patients with high-risk RMS or recurrent disease continue to respond inadequately to treatment and have poor survival outcomes.

Management of Patients with Genetic Predisposition to Breast Cancer

David M Euhus, MD, Maureen O’Donnell, MD
    • Recent legal and technological advances have popularized inexpensive, large multigene panels.
    • BRCA1 and BRCA2 are still the genes most frequently implicated in hereditary breast cancer predisposition. PALB2, CHEK2, and ATM are the next most common.
    • Most patients with a pathologic mutation in any of the breast cancer predisposition genes meet the criteria for enhanced surveillance with MRI.
    • Risk-reducing salpingo-oophorectomy provides a survival advantage and likely reduces breast cancer risk in BRCA2 carriers.
    • Breast cancers in women with pathologic mutations in DNA double-strand break repair genes show enhanced sensitivity to platin agents and PARP inhibitors.

Management of Patients with Genetic Predisposition to Breast Cancer

David M Euhus, MD, Maureen O’Donnell, MD
    • Recent legal and technological advances have popularized inexpensive, large multigene panels.
    • BRCA1 and BRCA2 are still the genes most frequently implicated in hereditary breast cancer predisposition. PALB2, CHEK2, and ATM are the next most common.
    • Most patients with a pathologic mutation in any of the breast cancer predisposition genes meet the criteria for enhanced surveillance with MRI.
    • Risk-reducing salpingo-oophorectomy provides a survival advantage and likely reduces breast cancer risk in BRCA2 carriers.
    • Breast cancers in women with pathologic mutations in DNA double-strand break repair genes show enhanced sensitivity to platin agents and PARP inhibitors.

Gastrointestinal Tract and Abdomen: Benign Diseases of the Peritoneum and Retroperitoneum

Amanda K. Arrington, MD
    • Hyperthermic intra-abdominal chemotherapy treatment in the setting of colorectal carcinomatosis, gastric carcinomatosis, pseudomyxoma peritonei
    • Nonsurgical treatment of peritonitis
    • Treatment strategies for intra-abdominal desmoid tumors

Leiomyosarcoma

Chiara Colombo, MD, Marco Fiore, MD, Sandro Pasquali, MD
    • Neoadjuvant chemotherapy with epirubicin and ifosfamide
    • Prognostic stratification
    • Extension of surgery in the retroperitoneum

Male Breast Cancer

Kimberly S. Stone, MD, Irene L Wapnir, MD
    • Recognition of inherited genetic predisposition for breast cancer, need for genetic counseling and genetic cancer screening
    • Appreciation that breast-conserving therapy is feasible and oncologically safe in men
    • Highlighting the recent inclusion of men with breast cancer in prospective national and international clinical trials
    • Recognition of unique biomarker characteristics of breast cancer in men and the impact on systemic therapeutic approaches

Male Breast Cancer

Kimberly S. Stone, MD, Irene L Wapnir, MD
    • Recognition of inherited genetic predisposition for breast cancer, need for genetic counseling and genetic cancer screening
    • Appreciation that breast-conserving therapy is feasible and oncologically safe in men
    • Highlighting the recent inclusion of men with breast cancer in prospective national and international clinical trials
    • Recognition of unique biomarker characteristics of breast cancer in men and the impact on systemic therapeutic approaches
« Previous | Next »
Updates per yearSpecialty updatesNumber of sections